uTR Biotech

Changing the face of Diabetes treatment

We hope to be treating type 1 and type 2 diabetes with a platform of products tailored specifically to symptoms associated with either stage of disease progression.

Our insulin research is primarily geared toward using a traditional formulation with an additive for alleviating the effects associated with chronic diabetes such as issues around microcirculation and neuropathy.

Our insulin will be formulated for having an expiration date between 12 and 24 months.